{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T16:10:15Z","timestamp":1787760615305,"version":"build-2784847793"},"reference-count":94,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2021,10,11]],"date-time":"2021-10-11T00:00:00Z","timestamp":1633910400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,10,11]],"date-time":"2021-10-11T00:00:00Z","timestamp":1633910400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006259","name":"teva pharmaceutical industries","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006259","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1007\/s40263-021-00861-6","type":"journal-article","created":{"date-parts":[[2021,10,11]],"date-time":"2021-10-11T12:03:39Z","timestamp":1633953819000},"page":"1189-1205","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":69,"title":["Controversies Surrounding the Use of Long-Acting Injectable Antipsychotic Medications for the Treatment of Patients with Schizophrenia"],"prefix":"10.1007","volume":"35","author":[{"given":"John M.","family":"Kane","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph P.","family":"McEvoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph U.","family":"Correll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Michel","family":"Llorca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,11]]},"reference":[{"issue":"10159","key":"861_CR1","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1016\/S0140-6736(18)32279-7","volume":"392","author":"GBD 2017 Disease and Injury Incidence and Prevalence Collaborators","year":"2018","unstructured":"GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1789\u2013858. https:\/\/doi.org\/10.1016\/S0140-6736(18)32279-7.","journal-title":"Lancet"},{"key":"861_CR2","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1093\/epirev\/mxn001","volume":"30","author":"J McGrath","year":"2008","unstructured":"McGrath J, Saha S, Chant D, Welham J. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev. 2008;30:67\u201376. https:\/\/doi.org\/10.1093\/epirev\/mxn001.","journal-title":"Epidemiol Rev"},{"issue":"3","key":"861_CR3","doi-asserted-by":"publisher","first-page":"e2658","DOI":"10.1002\/hup.2658","volume":"33","author":"P Girardi","year":"2018","unstructured":"Girardi P, Del Casale A, Rapinesi C, Kotzalidis GD, Splendori F, Verzura C, et al. Predictive factors of overall functioning improvement in patients with chronic schizophrenia and schizoaffective disorder treated with paliperidone palmitate and aripiprazole monohydrate [published correction appears in Hum Psychopharmacol. 2018;33(4):e2666]. Hum Psychopharmacol. 2018;33(3):e2658. https:\/\/doi.org\/10.1002\/hup.2658.","journal-title":"Hum Psychopharmacol"},{"issue":"4","key":"861_CR4","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1177\/2045125312474019","volume":"3","author":"K Higashi","year":"2013","unstructured":"Higashi K, Medic G, Littlewood KJ, Diez T, Granstrom O, De Hert M. Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review. Ther Adv Psychopharmacol. 2013;3(4):200\u201318. https:\/\/doi.org\/10.1177\/2045125312474019.","journal-title":"Ther Adv Psychopharmacol."},{"issue":"11","key":"861_CR5","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.18553\/jmcp.2016.22.11.1349","volume":"22","author":"JP MacEwan","year":"2016","unstructured":"MacEwan JP, Forma FM, Shafrin J, Hatch A, Lakdawalla DN, Lindenmayer JP. Patterns of adherence to oral atypical antipsychotics among patients diagnosed with schizophrenia. J Manag Care Spec Pharm. 2016;22(11):1349\u201361. https:\/\/doi.org\/10.18553\/jmcp.2016.22.11.1349.","journal-title":"J Manag Care Spec Pharm"},{"issue":"2","key":"861_CR6","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1192\/bjp.bp.113.127753","volume":"205","author":"M Penttil\u00e4","year":"2014","unstructured":"Penttil\u00e4 M, J\u00e4\u00e4skel\u00e4inen E, Hirvonen N, Isohanni M, Miettunen J. Duration of untreated psychosis as predictor of long-term outcome in schizophrenia: systematic review and meta-analysis. Br J Psychiatry. 2014;205(2):88\u201394. https:\/\/doi.org\/10.1192\/bjp.bp.113.127753.","journal-title":"Br J Psychiatry"},{"issue":"1","key":"861_CR7","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/wps.20822","volume":"20","author":"OD Howes","year":"2021","unstructured":"Howes OD, Whitehurst T, Shatalina E, Townsend L, Onwordi EC, Mak TLA, et al. The clinical significance of duration of untreated psychosis: an umbrella review and random-effects meta-analysis. World Psychiatry. 2021;20(1):75\u201395. https:\/\/doi.org\/10.1002\/wps.20822.","journal-title":"World Psychiatry"},{"key":"861_CR8","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/1471-244X-13-58","volume":"13","author":"P Geerts","year":"2013","unstructured":"Geerts P, Martinez G, Schreiner A. Attitudes towards the administration of long-acting antipsychotics: a survey of physicians and nurses. BMC Psychiatry. 2013;13:58. https:\/\/doi.org\/10.1186\/1471-244X-13-58.","journal-title":"BMC Psychiatry"},{"issue":"3","key":"861_CR9","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1002\/wps.20060","volume":"12","author":"JM Kane","year":"2013","unstructured":"Kane JM, Kishimoto T, Correll CU. Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies. World Psychiatry. 2013;12(3):216\u201326. https:\/\/doi.org\/10.1002\/wps.20060.","journal-title":"World Psychiatry"},{"issue":"5","key":"861_CR10","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1177\/2045125314540297","volume":"4","author":"S Brissos","year":"2014","unstructured":"Brissos S, Veguilla MR, Taylor D, Balanz\u00e1-Martinez V. The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal. Ther Adv Psychopharmacol. 2014;4(5):198\u2013219. https:\/\/doi.org\/10.1177\/2045125314540297.","journal-title":"Ther Adv Psychopharmacol."},{"issue":"4","key":"861_CR11","doi-asserted-by":"publisher","first-page":"505","DOI":"10.31887\/DCNS.2014.16.4\/mcarbon","volume":"16","author":"M Carbon","year":"2014","unstructured":"Carbon M, Correll CU. Clinical predictors of therapeutic response to antipsychotics in schizophrenia. Dialogues Clin Neurosci. 2014;16(4):505\u201324. https:\/\/doi.org\/10.31887\/DCNS.2014.16.4\/mcarbon.","journal-title":"Dialogues Clin Neurosci"},{"key":"861_CR12","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.2147\/NDT.S199048","volume":"15","author":"F Pietrini","year":"2019","unstructured":"Pietrini F, Albert U, Ballerini A, Calo P, Maina G, Pinna F, et al. The modern perspective for long-acting injectables antipsychotics in the patient-centered care of schizophrenia. Neuropsychiatr Dis Treat. 2019;15:1045\u201360. https:\/\/doi.org\/10.2147\/NDT.S199048.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"1\u20133","key":"861_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.schres.2016.09.015","volume":"178","author":"L Samalin","year":"2016","unstructured":"Samalin L, de Chazeron I, Blanc O, Brunel L, Fond G, Llorca PM. Attitudes toward antipsychotic medications as a useful feature in exploring medication non-adherence in schizophrenia. Schizophr Res. 2016;178(1\u20133):1\u20135. https:\/\/doi.org\/10.1016\/j.schres.2016.09.015.","journal-title":"Schizophr Res"},{"issue":"suppl 3","key":"861_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4088\/JCP.15032su1","volume":"77","author":"CU Correll","year":"2016","unstructured":"Correll CU, Citrome L, Haddad PM, Lauriello J, Olfson M, Calloway SM, et al. The use of long-acting injectable antipsychotics in schizophrenia: evaluating the evidence. J Clin Psychiatry. 2016;77(suppl 3):1\u201324. https:\/\/doi.org\/10.4088\/JCP.15032su1.","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"861_CR15","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s40263-020-00779-5","volume":"35","author":"CU Correll","year":"2021","unstructured":"Correll CU, Kim E, Sliwa JK, Hamm W, Gopal S, Mathews M, et al. Pharmacokinetic characteristics of long-acting injectable antipsychotics for schizophrenia: an overview. CNS Drugs. 2021;35(1):39\u201359. https:\/\/doi.org\/10.1007\/s40263-020-00779-5.","journal-title":"CNS Drugs"},{"issue":"sup1","key":"861_CR16","doi-asserted-by":"publisher","first-page":"S36","DOI":"10.1080\/08039488.2018.1525638","volume":"72","author":"DM Taylor","year":"2018","unstructured":"Taylor DM, Velaga S, Werneke U. Reducing the stigma of long acting injectable antipsychotics - current concepts and future developments published correction appears in Nord J Psychiatry. 2021;1]. Nord J Psychiatry. 2018;72(sup1):S36\u20139. https:\/\/doi.org\/10.1080\/08039488.2018.1525638.","journal-title":"Nord J Psychiatry"},{"issue":"5670","key":"861_CR17","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1136\/bmj.3.5670.564","volume":"3","author":"R De Alarcon","year":"1969","unstructured":"De Alarcon R, Carney MW. Severe depressive mood changes following slow-release intramuscular fluphenazine injection. Br Med J. 1969;3(5670):564\u20137. https:\/\/doi.org\/10.1136\/bmj.3.5670.564.","journal-title":"Br Med J"},{"key":"861_CR18","doi-asserted-by":"publisher","first-page":"205","DOI":"10.2147\/NDT.S188337","volume":"15","author":"N Sugawara","year":"2019","unstructured":"Sugawara N, Kudo S, Ishioka M, Sato Y, Kubo K, Yasui-Furukori N. Attitudes toward long-acting injectable antipsychotics among patients with schizophrenia in Japan. Neuropsychiatr Dis Treat. 2019;15:205\u201311. https:\/\/doi.org\/10.2147\/NDT.S188337.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"1","key":"861_CR19","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41537-020-00127-y","volume":"6","author":"CU Correll","year":"2020","unstructured":"Correll CU, Litman RE, Filts Y, Llaud\u00f3 J, Naber D, Torres F, et al. Efficacy and safety of once-monthly Risperidone ISM(\u00ae) in schizophrenic patients with an acute exacerbation. NPJ Schizophr. 2020;6(1):37. https:\/\/doi.org\/10.1038\/s41537-020-00127-y.","journal-title":"NPJ Schizophr"},{"key":"861_CR20","doi-asserted-by":"publisher","first-page":"757","DOI":"10.2147\/TCRM.S117321","volume":"13","author":"M Solmi","year":"2017","unstructured":"Solmi M, Murru A, Pacchiarotti I, Undurraga J, Veronese N, Fornaro M, et al. Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review. Ther Clin Risk Manag. 2017;13:757\u201377. https:\/\/doi.org\/10.2147\/TCRM.S117321.","journal-title":"Ther Clin Risk Manag"},{"issue":"12","key":"861_CR21","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1001\/jamapsychiatry.2020.2076","volume":"77","author":"JM Kane","year":"2020","unstructured":"Kane JM, Schooler NR, Marcy P, Correll CU, Achtyes ED, Gibbons RD, et al. Effect of long-acting injectable antipsychotics vs usual care on time to first hospitalization in early-phase schizophrenia: a randomized clinical trial [published correction appears in JAMA Psychiatry. 2020;77(12):1310]. JAMA Psychiat. 2020;77(12):1217\u201324. https:\/\/doi.org\/10.1001\/jamapsychiatry.2020.2076.","journal-title":"JAMA Psychiat"},{"issue":"8","key":"861_CR22","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1001\/jamapsychiatry.2015.0270","volume":"72","author":"KL Subotnik","year":"2015","unstructured":"Subotnik KL, Casaus LR, Ventura J, Luo JS, Hellemann GS, Gretchen-Doorly D, et al. Long-acting injectable risperidone for relapse prevention and control of breakthrough symptoms after a recent first episode of Schizophrenia. A randomized clinical trial. JAMA Psychiat. 2015;72(8):822\u20139. https:\/\/doi.org\/10.1001\/jamapsychiatry.2015.0270.","journal-title":"JAMA Psychiat"},{"issue":"11","key":"861_CR23","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.3390\/ijms17111935","volume":"17","author":"L Samalin","year":"2016","unstructured":"Samalin L, Garnier M, Auclair C, Llorca PM. Clinical decision-making in the treatment of schizophrenia: focus on long-acting injectable antipsychotics. Int J Mol Sci. 2016;17(11):1935. https:\/\/doi.org\/10.3390\/ijms17111935.","journal-title":"Int J Mol Sci"},{"key":"861_CR24","unstructured":"2019\u20132020 florida best practice psychotherapeutic medication guidelines for adults: University of South Florida, Florida Medicaid Drug Therapy Management Program sponsored by the Florida Agency for Health Care Administration; 2020. https:\/\/floridabhcenter.cbcs.usf.edu\/wp-content\/uploads\/2021\/04\/2019-Psychotherapeutic-Medication-Guidelines-for-Adults-with-References_06-04-20.pdf. Accessed 21 July 21."},{"key":"861_CR25","unstructured":"National Council for Behavioral Health. Guide to long-acting medications for providers and organizations. 2019. https:\/\/www.thenationalcouncil.org\/wp-content\/uploads\/2020\/05\/051220_NCBH_GuidetoLAMs_Live.pdf. Accessed 10 June 21."},{"issue":"9","key":"861_CR26","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1176\/appi.ajp.2020.177901","volume":"177","author":"GA Keepers","year":"2020","unstructured":"Keepers GA, Fochtmann LJ, Anzia JM, Benjamin S, Lyness JM, Mojtabai R, et al. The American Psychiatric Association Practice Guideline for the treatment of patients with schizophrenia. Am J Psychiatry. 2020;177(9):868\u201372. https:\/\/doi.org\/10.1176\/appi.ajp.2020.177901.","journal-title":"Am J Psychiatry"},{"key":"861_CR27","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1186\/1471-244X-13-340","volume":"13","author":"PM Llorca","year":"2013","unstructured":"Llorca PM, Abbar M, Courtet P, Guillaume S, Lancrenon S, Samalin L. Guidelines for the use and management of long-acting injectable antipsychotics in serious mental illness. BMC Psychiatry. 2013;13:340. https:\/\/doi.org\/10.1186\/1471-244X-13-340.","journal-title":"BMC Psychiatry"},{"key":"861_CR28","doi-asserted-by":"publisher","unstructured":"American Psychiatric Association. The American Psychiatric Association Practice Guideline for the treatment of patients with schizophrenia. 3rd ed; 2021. https:\/\/doi.org\/10.1176\/appi.books.9780890424841.","DOI":"10.1176\/appi.books.9780890424841"},{"issue":"10","key":"861_CR29","doi-asserted-by":"publisher","first-page":"892","DOI":"10.4088\/jcp.v63n1007","volume":"63","author":"JP Lacro","year":"2002","unstructured":"Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry. 2002;63(10):892\u2013909. https:\/\/doi.org\/10.4088\/jcp.v63n1007.","journal-title":"J Clin Psychiatry"},{"issue":"6","key":"861_CR30","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1111\/j.1742-1241.2012.02918.x","volume":"66","author":"JJ Stephenson","year":"2012","unstructured":"Stephenson JJ, Tunceli O, Gu T, Eisenberg D, Panish J, Crivera C, et al. Adherence to oral second-generation antipsychotic medications in patients with schizophrenia and bipolar disorder: physicians\u2019 perceptions of adherence vs. pharmacy claims. Int J Clin Pract. 2012;66(6):565\u201373. https:\/\/doi.org\/10.1111\/j.1742-1241.2012.02918.x.","journal-title":"Int J Clin Pract"},{"issue":"6","key":"861_CR31","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1176\/appi.ajp.2011.10081224","volume":"168","author":"J Tiihonen","year":"2011","unstructured":"Tiihonen J, Haukka J, Taylor M, Haddad PM, Patel MX, Korhonen P. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia [published correction appears in Am J Psychiatry. 2012;169(2):223]. Am J Psychiatry. 2011;168(6):603\u20139. https:\/\/doi.org\/10.1176\/appi.ajp.2011.10081224.","journal-title":"Am J Psychiatry"},{"issue":"2","key":"861_CR32","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1080\/13696998.2017.1379412","volume":"21","author":"M Greene","year":"2018","unstructured":"Greene M, Yan T, Chang E, Hartry A, Touya M, Broder MS. Medication adherence and discontinuation of long-acting injectable versus oral antipsychotics in patients with schizophrenia or bipolar disorder. J Med Econ. 2018;21(2):127\u201334. https:\/\/doi.org\/10.1080\/13696998.2017.1379412.","journal-title":"J Med Econ"},{"issue":"1","key":"861_CR33","doi-asserted-by":"publisher","DOI":"10.1192\/j.eurpsy.2021.4","volume":"64","author":"E Laing","year":"2021","unstructured":"Laing E, Taylor D. Relapse and frequency of injection of monthly paliperidone palmitate-A retrospective case-control study. Eur Psychiatry. 2021;64(1): e11. https:\/\/doi.org\/10.1192\/j.eurpsy.2021.4.","journal-title":"Eur Psychiatry"},{"key":"861_CR34","doi-asserted-by":"publisher","first-page":"204512532092478","DOI":"10.1177\/2045125320924789","volume":"10","author":"S Pappa","year":"2020","unstructured":"Pappa S, Mason K. Partial compliance with long-acting paliperidone palmitate and impact on hospitalization: a 6-year mirror-image study. Ther Adv Psychopharmacol. 2020;10:2045125320924789. https:\/\/doi.org\/10.1177\/2045125320924789.","journal-title":"Ther Adv Psychopharmacol."},{"issue":"6","key":"861_CR35","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1093\/schbul\/sbm033","volume":"33","author":"M Olfson","year":"2007","unstructured":"Olfson M, Marcus SC, Ascher-Svanum H. Treatment of schizophrenia with long-acting fluphenazine, haloperidol, or risperidone. Schizophr Bull. 2007;33(6):1379\u201387. https:\/\/doi.org\/10.1093\/schbul\/sbm033.","journal-title":"Schizophr Bull"},{"issue":"7","key":"861_CR36","doi-asserted-by":"publisher","first-page":"e813","DOI":"10.4088\/JCP.16m11308","volume":"78","author":"PJ Weiden","year":"2017","unstructured":"Weiden PJ, Kim E, Bermak J, Turkoz I, Gopal S, Berwaerts J. Does half-life matter after antipsychotic discontinuation? A relapse comparison in schizophrenia with 3 different formulations of paliperidone. J Clin Psychiatry. 2017;78(7):e813\u201320. https:\/\/doi.org\/10.4088\/JCP.16m11308.","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"861_CR37","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/S2215-0366(21)00039-0","volume":"8","author":"T Kishimoto","year":"2021","unstructured":"Kishimoto T, Hagi K, Kurokawa S, Kane JM, Correll CU. Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre-post studies. Lancet Psychiatry. 2021;8(5):387\u2013404. https:\/\/doi.org\/10.1016\/S2215-0366(21)00039-0.","journal-title":"Lancet Psychiatry"},{"issue":"5","key":"861_CR38","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1097\/YIC.0000000000000082","volume":"30","author":"CA Bossie","year":"2015","unstructured":"Bossie CA, Alphs LD, Correll CU. Long-acting injectable versus daily oral antipsychotic treatment trials in schizophrenia: pragmatic versus explanatory study designs. Int Clin Psychopharmacol. 2015;30(5):272. https:\/\/doi.org\/10.1097\/YIC.0000000000000082.","journal-title":"Int Clin Psychopharmacol"},{"issue":"5","key":"861_CR39","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1097\/JCP.0b013e3181f14098","volume":"30","author":"D Novick","year":"2010","unstructured":"Novick D, Haro JM, Bertsch J, Haddad PM. Incidence of extrapyramidal symptoms and tardive dyskinesia in schizophrenia: thirty-six-month results from the European schizophrenia outpatient health outcomes study. J Clin Psychopharmacol. 2010;30(5):531\u201340. https:\/\/doi.org\/10.1097\/JCP.0b013e3181f14098.","journal-title":"J Clin Psychopharmacol"},{"key":"861_CR40","doi-asserted-by":"publisher","first-page":"S63","DOI":"10.1192\/bjp.195.52.s63","volume":"52","author":"JM Kane","year":"2009","unstructured":"Kane JM, Garcia-Ribera C. Clinical guideline recommendations for antipsychotic long-acting injections. Br J Psychiatry Suppl. 2009;52:S63. https:\/\/doi.org\/10.1192\/bjp.195.52.s63.","journal-title":"Br J Psychiatry Suppl"},{"key":"861_CR41","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.jns.2018.02.015","volume":"389","author":"SN Caroff","year":"2018","unstructured":"Caroff SN, Ungvari GS, Cunningham Owens DG. Historical perspectives on tardive dyskinesia. J Neurol Sci. 2018;389:4\u20139. https:\/\/doi.org\/10.1016\/j.jns.2018.02.015.","journal-title":"J Neurol Sci"},{"issue":"2\u20133","key":"861_CR42","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.schres.2016.07.018","volume":"176","author":"F Misawa","year":"2016","unstructured":"Misawa F, Kishimoto T, Hagi K, Kane JM, Correll CU. Safety and tolerability of long-acting injectable versus oral antipsychotics: A meta-analysis of randomized controlled studies comparing the same antipsychotics. Schizophr Res. 2016;176(2\u20133):220. https:\/\/doi.org\/10.1016\/j.schres.2016.07.018.","journal-title":"Schizophr Res"},{"issue":"24","key":"861_CR43","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1093\/ajhp\/zxaa303","volume":"77","author":"JM Noel","year":"2020","unstructured":"Noel JM, Jackson CW. ASHP therapeutic position statement on the use of antipsychotic medications in the treatment of adults with schizophrenia and schizoaffective disorder. Am J Health Syst Pharm. 2020;77(24):2114\u201332. https:\/\/doi.org\/10.1093\/ajhp\/zxaa303.","journal-title":"Am J Health Syst Pharm"},{"issue":"1","key":"861_CR44","doi-asserted-by":"publisher","first-page":"20r13272","DOI":"10.4088\/JCP.20r13272","volume":"82","author":"D Guinart","year":"2020","unstructured":"Guinart D, Misawa F, Rubio JM, Pereira J, Sharma H, Schoretsanitis G, et al. Outcomes of neuroleptic malignant syndrome with depot versus oral antipsychotics: a systematic review and pooled, patient-level analysis of 662 case reports. J Clin Psychiatry. 2020;82(1):20r13272. https:\/\/doi.org\/10.4088\/JCP.20r13272.","journal-title":"J Clin Psychiatry"},{"key":"861_CR45","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/1471-244X-13-50","volume":"13","author":"R Emsley","year":"2013","unstructured":"Emsley R, Chiliza B, Asmal L, Harvey BH. The nature of relapse in schizophrenia. BMC Psychiatry. 2013;13:50. https:\/\/doi.org\/10.1186\/1471-244X-13-50.","journal-title":"BMC Psychiatry"},{"issue":"6","key":"861_CR46","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1038\/s41386-018-0278-3","volume":"44","author":"H Takeuchi","year":"2019","unstructured":"Takeuchi H, Siu C, Remington G, Fervaha G, Zipursky RB, Foussias G, et al. Does relapse contribute to treatment resistance? Antipsychotic response in first- vs. second-episode schizophrenia. Neuropsychopharmacology. 2019;44(6):1036\u201342. https:\/\/doi.org\/10.1038\/s41386-018-0278-3.","journal-title":"Neuropsychopharmacology"},{"key":"861_CR47","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852918001098","author":"CU Correll","year":"2018","unstructured":"Correll CU, Sliwa JK, Najarian DM, Saklad SR. Practical considerations for managing breakthrough psychosis and symptomatic worsening in patients with schizophrenia on long-acting injectable antipsychotics. CNS Spectr. 2018. https:\/\/doi.org\/10.1017\/S1092852918001098.","journal-title":"CNS Spectr"},{"key":"861_CR48","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.schres.2019.11.025","volume":"225","author":"R Emsley","year":"2020","unstructured":"Emsley R, Asmal L, Rubio JM, Correll CU, Kane JM. Predictors of psychosis breakthrough during 24 months of long-acting antipsychotic maintenance treatment in first episode schizophrenia. Schizophr Res. 2020;225:55\u201362. https:\/\/doi.org\/10.1016\/j.schres.2019.11.025.","journal-title":"Schizophr Res"},{"issue":"8","key":"861_CR49","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1017\/S0033291719001296","volume":"50","author":"JM Rubio","year":"2020","unstructured":"Rubio JM, Taipale H, Correll CU, Tanskanen A, Kane JM, Tiihonen J. Psychosis breakthrough on antipsychotic maintenance: results from a nationwide study. Psychol Med. 2020;50(8):1356\u201367. https:\/\/doi.org\/10.1017\/S0033291719001296.","journal-title":"Psychol Med"},{"issue":"9","key":"861_CR50","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/S2215-0366(20)30264-9","volume":"7","author":"JM Rubio","year":"2020","unstructured":"Rubio JM, Schoretsanitis G, John M, Tiihonen J, Taipale H, Guinart D, et al. Psychosis relapse during treatment with long-acting injectable antipsychotics in individuals with schizophrenia-spectrum disorders: an individual participant data meta-analysis. Lancet Psychiatry. 2020;7(9):749\u2013749. https:\/\/doi.org\/10.1016\/S2215-0366(20)30264-9.","journal-title":"Lancet Psychiatry"},{"key":"861_CR51","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.schres.2017.12.010","volume":"197","author":"H Taipale","year":"2018","unstructured":"Taipale H, Mittendorfer-Rutz E, Alexanderson K, Majak M, Mehtala J, Hoti F, et al. Antipsychotics and mortality in a nationwide cohort of 29,823 patients with schizophrenia. Schizophr Res. 2018;197:274\u201380. https:\/\/doi.org\/10.1016\/j.schres.2017.12.010.","journal-title":"Schizophr Res"},{"issue":"1","key":"861_CR52","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1002\/wps.20699","volume":"19","author":"H Taipale","year":"2020","unstructured":"Taipale H, Tanskanen A, Mehtala J, Vattulainen P, Correll CU, Tiihonen J. 20-year follow-up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62,250 patients with schizophrenia (FIN20). World Psychiatry. 2020;19(1):61\u20138. https:\/\/doi.org\/10.1002\/wps.20699.","journal-title":"World Psychiatry"},{"issue":"8","key":"861_CR53","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1176\/appi.ajp.2018.17091001","volume":"175","author":"J Tiihonen","year":"2018","unstructured":"Tiihonen J, Tanskanen A, Taipale H. 20-year nationwide follow-up study on discontinuation of antipsychotic treatment in first-episode schizophrenia. Am J Psychiatry. 2018;175(8):765\u201373. https:\/\/doi.org\/10.1176\/appi.ajp.2018.17091001.","journal-title":"Am J Psychiatry"},{"issue":"1","key":"861_CR54","first-page":"12","volume":"1","author":"MV Seeman","year":"2017","unstructured":"Seeman MV. Drawbacks of long-acting intramuscular antipsychotic injections. J Clin Pract Nurs. 2017;1(1):12\u201322.","journal-title":"J Clin Pract Nurs."},{"key":"861_CR55","doi-asserted-by":"publisher","first-page":"449","DOI":"10.2147\/PPA.S124658","volume":"11","author":"DI Velligan","year":"2017","unstructured":"Velligan DI, Sajatovic M, Hatch A, Kramata P, Docherty JP. Why do psychiatric patients stop antipsychotic medication? A systematic review of reasons for nonadherence to medication in patients with serious mental illness. Patient Prefer Adherence. 2017;11:449\u201368. https:\/\/doi.org\/10.2147\/PPA.S124658.","journal-title":"Patient Prefer Adherence"},{"issue":"7","key":"861_CR56","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1097\/NMD.0b013e31829829c4","volume":"201","author":"L Samalin","year":"2013","unstructured":"Samalin L, Charpeaud T, Blanc O, Heres S, Llorca PM. Clinicians\u2019 attitudes toward the use of long-acting injectable antipsychotics. J Nerv Ment Dis. 2013;201(7):553\u20139. https:\/\/doi.org\/10.1097\/NMD.0b013e31829829c4.","journal-title":"J Nerv Ment Dis"},{"key":"861_CR57","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.2147\/NDT.S167394","volume":"14","author":"M Sajatovic","year":"2018","unstructured":"Sajatovic M, Ross R, Legacy SN, Correll CU, Kane JM, DiBiasi F, et al. Identifying patients and clinical scenarios for use of long-acting injectable antipsychotics - expert consensus survey part 1. Neuropsychiatr Dis Treat. 2018;14:1463. https:\/\/doi.org\/10.2147\/NDT.S167394.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"6","key":"861_CR58","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1111\/eip.12770","volume":"13","author":"M Horvitz-Lennon","year":"2019","unstructured":"Horvitz-Lennon M, Predmore Z, Orr P, Hanson M, Hillestad R, Durkin M, et al. Simulated long-term outcomes of early use of long-acting injectable antipsychotics in early schizophrenia. Early Interv Psychiatry. 2019;13(6):1357\u201365. https:\/\/doi.org\/10.1111\/eip.12770.","journal-title":"Early Interv Psychiatry"},{"key":"861_CR59","unstructured":"Guzman F. Long-acting injectable antipsychotics: a practical guide for prescribers. 27 June 2019 [cited 16 June 2020]. https:\/\/psychopharmacologyinstitute.com\/publication\/long-acting-injectable-antipsychotics-a-practical-guide-for-prescribers-2201."},{"key":"861_CR60","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.2147\/NDT.S167485","volume":"14","author":"M Sajatovic","year":"2018","unstructured":"Sajatovic M, Ross R, Legacy SN, Byerly M, Kane JM, DiBiasi F, et al. Initiating\/maintaining long-acting injectable antipsychotics in schizophrenia\/schizoaffective or bipolar disorder\u2014expert consensus survey part 2. Neuropsychiatr Dis Treat. 2018;14:1475\u201392. https:\/\/doi.org\/10.2147\/NDT.S167485.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"3","key":"861_CR61","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1176\/appi.ajp.2016.16050503","volume":"174","author":"OD Howes","year":"2017","unstructured":"Howes OD, McCutcheon R, Agid O, de Bartolomeis A, van Beveren NJ, Birnbaum ML, et al. Treatment-resistant schizophrenia: treatment response and resistance in psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology. Am J Psychiatry. 2017;174(3):216\u201329. https:\/\/doi.org\/10.1176\/appi.ajp.2016.16050503.","journal-title":"Am J Psychiatry"},{"issue":"3","key":"861_CR62","doi-asserted-by":"publisher","first-page":"MS19053BR4C","DOI":"10.4088\/JCP.MS19053BR4C","volume":"81","author":"J Lauriello","year":"2020","unstructured":"Lauriello J. Patient-centered psychopharmacology and psychosocial interventions: treatment selection and shared decision-making to enhance chances for recovery. J Clin Psychiatry. 2020;81(3):MS19053BR4C. https:\/\/doi.org\/10.4088\/JCP.MS19053BR4C.","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"861_CR63","doi-asserted-by":"publisher","first-page":"MS19053AH5C","DOI":"10.4088\/JCP.MS19053AH5C","volume":"81","author":"CU Correll","year":"2020","unstructured":"Correll CU, Lauriello J. Using long-acting injectable antipsychotics to enhance the potential for recovery in schizophrenia. J Clin Psychiatry. 2020;81(4):MS19053AH5C. https:\/\/doi.org\/10.4088\/JCP.MS19053AH5C.","journal-title":"J Clin Psychiatry"},{"issue":"6","key":"861_CR64","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1192\/bjp.bp.110.085340","volume":"199","author":"S Farooq","year":"2011","unstructured":"Farooq S, Nazar Z, Irfan M, Akhter J, Gul E, Irfan U, et al. Schizophrenia medication adherence in a resource-poor setting: randomised controlled trial of supervised treatment in out-patients for schizophrenia (STOPS). Br J Psychiatry. 2011;199(6):467\u201372. https:\/\/doi.org\/10.1192\/bjp.bp.110.085340.","journal-title":"Br J Psychiatry"},{"key":"861_CR65","doi-asserted-by":"publisher","first-page":"165","DOI":"10.2147\/PPA.S15337","volume":"5","author":"F Caroli","year":"2011","unstructured":"Caroli F, Raymondet P, Izard I, Plas J, Gall B, Delgado A. Opinions of French patients with schizophrenia regarding injectable medication. Patient Prefer Adherence. 2011;5:165\u201371. https:\/\/doi.org\/10.2147\/PPA.S15337.","journal-title":"Patient Prefer Adherence"},{"issue":"8","key":"861_CR66","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1080\/14656566.2016.1174692","volume":"17","author":"L Hargarter","year":"2016","unstructured":"Hargarter L, Bergmans P, Cherubin P, Keim S, Conca A, Serrano-Blanco A, et al. Once-monthly paliperidone palmitate in recently diagnosed and chronic non-acute patients with schizophrenia. Expert Opin Pharmacother. 2016;17(8):1043\u201353. https:\/\/doi.org\/10.1080\/14656566.2016.1174692.","journal-title":"Expert Opin Pharmacother"},{"issue":"4","key":"861_CR67","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1111\/eip.12868","volume":"14","author":"B Brown","year":"2020","unstructured":"Brown B, Turkoz I, Mancevski B, Mathews M. Evaluation of paliperidone palmitate long-acting injectable antipsychotic therapy as an early treatment option in patients with schizophrenia. Early Interv Psychiatry. 2020;14(4):428\u201338. https:\/\/doi.org\/10.1111\/eip.12868.","journal-title":"Early Interv Psychiatry"},{"key":"861_CR68","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.20m13446","author":"S Kim","year":"2021","unstructured":"Kim S, Kim S, Koh M, Choi G, Kim JJ, Paik IH, et al. Effects of long-acting injectable paliperidone palmitate on clinical and functional outcomes in patients with schizophrenia based on illness duration. J Clin Psychiatry. 2021. https:\/\/doi.org\/10.4088\/JCP.20m13446.","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"861_CR69","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1177\/2045125312464106","volume":"3","author":"M Kirschner","year":"2013","unstructured":"Kirschner M, Theodoridou A, Fusar-Poli P, Kaiser S, J\u00e4ger M. Patients\u2019 and clinicians\u2019 attitude towards long-acting depot antipsychotics in subjects with a first episode of psychosis. Ther Adv Psychopharmacol. 2013;3(2):89\u201399. https:\/\/doi.org\/10.1177\/2045125312464106.","journal-title":"Ther Adv Psychopharmacol."},{"issue":"11","key":"861_CR70","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.13024tx3c","volume":"75","author":"CU Correll","year":"2014","unstructured":"Correll CU. Recognition of patients who would benefit from LAI antipsychotic treatment: how to assess adherence. J Clin Psychiatry. 2014;75(11): e29. https:\/\/doi.org\/10.4088\/JCP.13024tx3c.","journal-title":"J Clin Psychiatry"},{"issue":"6","key":"861_CR71","doi-asserted-by":"publisher","first-page":"684","DOI":"10.4088\/JCP.13m08946","volume":"76","author":"PJ Weiden","year":"2015","unstructured":"Weiden PJ, Roma RS, Velligan DI, Alphs L, DiChiara M, Davidson B. The challenge of offering long-acting antipsychotic therapies: a preliminary discourse analysis of psychiatrist recommendations for injectable therapy to patients with schizophrenia. J Clin Psychiatry. 2015;76(6):684\u201390. https:\/\/doi.org\/10.4088\/JCP.13m08946.","journal-title":"J Clin Psychiatry"},{"key":"861_CR72","unstructured":"Working Group of the Clinical Practice Guideline for Schizophrenia and Incipient Psychotic Disorder, Mental Health Forum, coordination. Clinical Practice Guideline for Schizophrenia and Incipient Psychotic Disorder. Clinical Practice Guideline: CAHTA. Number 2006\/05-2. Madrid: Quality Plan for the National Health System of the Ministry of Health and Consumer Affairs. Agency for Health Technology Assessment and Research; 2009. https:\/\/portal.guiasalud.es\/wp-content\/uploads\/2019\/01\/GPC_495_Schizophrenia_compl_en.pdf. Accessed 26 July 2021."},{"issue":"5","key":"861_CR73","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1177\/0004867416641195","volume":"50","author":"C Galletly","year":"2016","unstructured":"Galletly C, Castle D, Dark F, Humberstone V, Jablensky A, Killackey E, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders. Aust N Z J Psychiatry. 2016;50(5):410\u201372. https:\/\/doi.org\/10.1177\/0004867416641195.","journal-title":"Aust N Z J Psychiatry"},{"issue":"2","key":"861_CR74","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1111\/appy.12234","volume":"8","author":"TL Lo","year":"2016","unstructured":"Lo TL, Warden M, He Y, Si T, Kalyanasundaram S, Thirunavukarasu M, et al. Recommendations for the optimal care of patients with recent-onset psychosis in the Asia-Pacific region. Asia Pac Psychiatry. 2016;8(2):154\u201371. https:\/\/doi.org\/10.1111\/appy.12234.","journal-title":"Asia Pac Psychiatry"},{"issue":"4","key":"861_CR75","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1176\/appi.ps.201900236","volume":"71","author":"DG Robinson","year":"2020","unstructured":"Robinson DG, Subramaniam A, Fearis PJ, Shi R, Walsh M, Hanna LA, et al. Focused ethnographic examination of barriers to use of long-acting injectable antipsychotics. Psychiatr Serv. 2020;71(4):337\u201342. https:\/\/doi.org\/10.1176\/appi.ps.201900236.","journal-title":"Psychiatr Serv"},{"issue":"11","key":"861_CR76","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1177\/2045125318782694","volume":"8","author":"E Stip","year":"2018","unstructured":"Stip E, Lachaine J. Real-world effectiveness of long-acting antipsychotic treatments in a nationwide cohort of 3957 patients with schizophrenia, schizoaffective disorder and other diagnoses in Quebec [published correction appears in Ther Adv Psychopharmacol. 2018;8(11):327]. Ther Adv Psychopharmacol. 2018;8(11):287\u2013301. https:\/\/doi.org\/10.1177\/2045125318782694.","journal-title":"Ther Adv Psychopharmacol."},{"issue":"6","key":"861_CR77","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1007\/s10597-011-9389-6","volume":"47","author":"DI Velligan","year":"2011","unstructured":"Velligan DI, Medellin E, Draper M, Maples N, Dassori A, Moore TA, et al. Barriers to, and strategies for, starting a long acting injection clinic in a community mental health center. Community Ment Health J. 2011;47(6):654\u20139. https:\/\/doi.org\/10.1007\/s10597-011-9389-6.","journal-title":"Community Ment Health J"},{"issue":"3","key":"861_CR78","doi-asserted-by":"publisher","first-page":"18312546","DOI":"10.4088\/JCP.18m12546","volume":"80","author":"JM Kane","year":"2019","unstructured":"Kane JM, Schooler NR, Marcy P, Achtyes ED, Correll CU, Robinson DG. Patients with early-phase schizophrenia will accept treatment with sustained-release medication (long-acting injectable antipsychotics): results from the recruitment phase of the PRELAPSE trial. J Clin Psychiatry. 2019;80(3):18312546. https:\/\/doi.org\/10.4088\/JCP.18m12546.","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"861_CR79","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1176\/appi.ps.201800362","volume":"70","author":"J Hamann","year":"2019","unstructured":"Hamann J, Heres S. Why and how family caregivers should participate in shared decision making in mental health. Psychiatr Serv. 2019;70(5):418\u201321. https:\/\/doi.org\/10.1176\/appi.ps.201800362.","journal-title":"Psychiatr Serv"},{"issue":"3","key":"861_CR80","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0230051","volume":"15","author":"V Latorre","year":"2020","unstructured":"Latorre V, Papazacharias A, Lorusso M, Nappi G, Clemente P, Spinelli A, et al. Improving the \u201creal life\u201d management of schizophrenia spectrum disorders by LAI antipsychotics: a one-year mirror-image retrospective study in community mental health services. PLoS ONE. 2020;15(3): e0230051. https:\/\/doi.org\/10.1371\/journal.pone.0230051.","journal-title":"PLoS ONE"},{"issue":"3","key":"861_CR81","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1037\/\/0894-4105.12.3.426","volume":"12","author":"RW Heinrichs","year":"1998","unstructured":"Heinrichs RW, Zakzanis KK. Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology. 1998;12(3):426\u201345. https:\/\/doi.org\/10.1037\/\/0894-4105.12.3.426.","journal-title":"Neuropsychology"},{"issue":"2","key":"861_CR82","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/nrd3628","volume":"11","author":"MJ Millan","year":"2012","unstructured":"Millan MJ, Agid Y, Brune M, Bullmore ET, Carter CS, Clayton NS, et al. Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy. Nat Rev Drug Discov. 2012;11(2):141\u201368. https:\/\/doi.org\/10.1038\/nrd3628.","journal-title":"Nat Rev Drug Discov"},{"issue":"7","key":"861_CR83","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1176\/appi.ajp.157.7.1167","volume":"157","author":"LA Flashman","year":"2000","unstructured":"Flashman LA, McAllister TW, Andreasen NC, Saykin AJ. Smaller brain size associated with unawareness of illness in patients with schizophrenia. Am J Psychiatry. 2000;157(7):1167\u20139. https:\/\/doi.org\/10.1176\/appi.ajp.157.7.1167.","journal-title":"Am J Psychiatry"},{"key":"861_CR84","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.schres.2018.10.013","volume":"206","author":"L Phahladira","year":"2019","unstructured":"Phahladira L, Asmal L, Kilian S, Chiliza B, Scheffler F, Luckhoff HK, et al. Changes in insight over the first 24 months of treatment in schizophrenia spectrum disorders. Schizophr Res. 2019;206:394\u20139. https:\/\/doi.org\/10.1016\/j.schres.2018.10.013.","journal-title":"Schizophr Res"},{"issue":"3","key":"861_CR85","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/S2215-0366(17)30045-7","volume":"4","author":"EL Noordraven","year":"2017","unstructured":"Noordraven EL, Wierdsma AI, Blanken P, Bloemendaal AF, Staring AB, Mulder CL. Financial incentives for improving adherence to maintenance treatment in patients with psychotic disorders (Money for Medication): a multicentre, open-label, randomised controlled trial. Lancet Psychiatry. 2017;4(3):199\u2013207. https:\/\/doi.org\/10.1016\/S2215-0366(17)30045-7.","journal-title":"Lancet Psychiatry"},{"issue":"70","key":"861_CR86","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta20700","volume":"20","author":"S Priebe","year":"2016","unstructured":"Priebe S, Bremner SA, Lauber C, Henderson C, Burns T. Financial incentives to improve adherence to antipsychotic maintenance medication in non-adherent patients: a cluster randomised controlled trial. Health Technol Assess. 2016;20(70):1\u2013122. https:\/\/doi.org\/10.3310\/hta20700.","journal-title":"Health Technol Assess"},{"issue":"4","key":"861_CR87","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1136\/jme.2006.016188","volume":"33","author":"D Claassen","year":"2007","unstructured":"Claassen D. Financial incentives for antipsychotic depot medication: ethical issues. J Med Ethics. 2007;33(4):189\u201393. https:\/\/doi.org\/10.1136\/jme.2006.016188.","journal-title":"J Med Ethics"},{"key":"861_CR88","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1002\/bsl.2370110303","volume":"11","author":"A Wertheimer","year":"1993","unstructured":"Wertheimer A. A philosophical examination of coercion for mental health issues. Behav Sci Law. 1993;11:239\u201358.","journal-title":"Behav Sci Law"},{"issue":"10","key":"861_CR89","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1176\/appi.ps.201900116","volume":"70","author":"D Guinart","year":"2019","unstructured":"Guinart D, Kane JM. Use of behavioral economics to improve medication adherence in severe mental illness. Psychiatr Serv. 2019;70(10):955\u20137. https:\/\/doi.org\/10.1176\/appi.ps.201900116.","journal-title":"Psychiatr Serv"},{"issue":"2","key":"861_CR90","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1002\/wps.20516","volume":"17","author":"CU Correll","year":"2018","unstructured":"Correll CU, Rubio JM, Kane JM. What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia? World Psychiatry. 2018;17(2):149\u201360. https:\/\/doi.org\/10.1002\/wps.20516.","journal-title":"World Psychiatry"},{"issue":"6","key":"861_CR91","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1177\/1039856217734711","volume":"25","author":"V Alguera-Lara","year":"2017","unstructured":"Alguera-Lara V, Dowsey MM, Ride J, Kinder S, Castle D. Shared decision making in mental health: the importance for current clinical practice. Australas Psychiatry. 2017;25(6):578\u201382. https:\/\/doi.org\/10.1177\/1039856217734711.","journal-title":"Australas Psychiatry"},{"issue":"5","key":"861_CR92","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1097\/JCP.0000000000000766","volume":"37","author":"A Foster","year":"2017","unstructured":"Foster A, Buckley P, Lauriello J, Looney S, Schooler N. Combination antipsychotic therapies: an analysis from a longitudinal pragmatic trial. J Clin Psychopharmacol. 2017;37(5):595\u20139. https:\/\/doi.org\/10.1097\/JCP.0000000000000766.","journal-title":"J Clin Psychopharmacol"},{"issue":"6","key":"861_CR93","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1093\/schbul\/sbx176","volume":"44","author":"H Taipale","year":"2018","unstructured":"Taipale H, Mehtala J, Tanskanen A, Tiihonen J. Comparative effectiveness of antipsychotic drugs for rehospitalization in schizophrenia-a nationwide study with 20-year follow-up [published correction appears in Schizophr Bull. 2019;45(6):1381]. Schizophr Bull. 2018;44(6):1381\u20137. https:\/\/doi.org\/10.1093\/schbul\/sbx176.","journal-title":"Schizophr Bull"},{"issue":"3","key":"861_CR94","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1002\/wps.20579","volume":"17","author":"M Carbon","year":"2018","unstructured":"Carbon M, Kane JM, Leucht S, Correll CU. Tardive dyskinesia risk with first- and second-generation antipsychotics in comparative randomized controlled trials: a meta-analysis. World Psychiatry. 2018;17(3):330\u201340. https:\/\/doi.org\/10.1002\/wps.20579.","journal-title":"World Psychiatry"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-021-00861-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-021-00861-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-021-00861-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,27]],"date-time":"2021-10-27T06:30:27Z","timestamp":1635316227000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-021-00861-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,11]]},"references-count":94,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["861"],"URL":"https:\/\/doi.org\/10.1007\/s40263-021-00861-6","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,11]]},"assertion":[{"value":"23 August 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Funding for this publication and editorial support was provided by Teva Pharmaceutical Industries, West Chester, PA, USA.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"John M. Kane has been a consultant for or received honoraria from Alkermes, Intra-Cellular Therapies, Janssen, Johnson and Johnson, Karuna, LB Pharmaceuticals, Lundbeck, Lyndra, Merck, Neurocrine Biosciences, Otsuka, Pierre Fabre, Reviva, Roche, Saladex, Sunovion, Takeda, and Teva Pharmaceutical Industries; has received grant support from Otsuka, Lundbeck, and Janssen; and is a shareholder of LB Pharmaceuticals and Vanguard Research Group. Joseph P. McEvoy has received grant\/research support from Alkermes, Auspex Pharmaceuticals (Teva Pharmaceutical Industries), Biogen, Boehringer Ingelheim, Lundbeck, and Takeda and has served on advisory boards for Intra-Cellular Therapies and Sunovion. Christoph U. Correll has been a consultant for or has received honoraria from AbbVie, Acadia Pharmaceuticals, Alkermes, Allergan, Angelini, Axsome Therapeutics, Gedeon Richter, Intra-Cellular Therapies, Janssen, Johnson & Johnson, Karuna, LB Pharmaceuticals, Laboratorios Farmac\u00e9uticos ROVI, Lundbeck, MedAvante-ProPhase, MedInCell, Medscape, Merck, Mitsubishi Tanabe Pharma, Mylan, Neurocrine, Noven, Otsuka, Pfizer, Recordati, Seqirus, Servier, Sumitomo Dainippon, Sunovion, Supernus Pharmaceuticals, Takeda, Teva Pharmaceutical Industries, and Viatris; has provided expert testimony for Janssen and Otsuka; has served on data safety monitoring boards or advisory boards for Laboratorios Farmac\u00e9uticos ROVI, Lundbeck, Supernus, and Teva Pharmaceutical Industries; has received grant support from Janssen and Takeda; has received royalties from UpToDate; serves on the board of directors for the American Society of Clinical Psychopharmacology; and is a shareholder of LB Pharmaceuticals. Pierre-Michel Llorca has been a consultant for or has received honoraria from AbbVie, Allergan, Eisai, Gedeon Richter, Janssen, Lundbeck, Otsuka, Sanofi, and Teva Pharmaceutical Industries; has received travel support from Eisai, Lundbeck, and Janssen; has served on data safety monitoring boards or advisory boards for AbbVie, Allergan, Eisai, Janssen, Lundbeck, Otsuka, Sanofi, and Teva Pharmaceutical Industries; and has received grant support from and provided expert testimony for Janssen.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Not applicable","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent"}},{"value":"All authors contributed equally to the conception, literature review, drafting, and review processes related to this publication. All authors approved the final version of the manuscript for submission and agree to be accountable for the information presented in this publication.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}